Osteoimmunomodulation of astragalus-calcium silicate scaffolds-activated M2 macrophage-derived miR-218-rich exosome for enhanced bone regeneration
Materials Today Bio · 2025-12 · 35 · 102286
DOI: 10.1016/j.mtbio.2025.102286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Materials Today Bio, 2025-12. Verfasst von Cheng-Yu Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Research & Development Center for x-Dimensional Extracellular Vesicles, China Medical University Hospital, Taichung, 404332, Taiwan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science and Technology Council, China Medical University Hospital.
Abstract (Originalsprache)
Current therapeutic strategies for bone defects, including autografts, allografts, and conventional biomaterial scaffolds, are limited by donor site morbidity, immune rejection, and insufficient vascularization. Moreover, the complex inflammatory microenvironment in bone defects often impairs healing outcomes, necessitating the development of advanced biomaterials with enhanced immunomodulatory and regenerative capabilities. This study investigates the therapeutic potential of extracellular vesicles derived from Astragalus-modified calcium silicate (AstCS)-stimulated M2 macrophages (AstCSM2EVs) in bone regeneration. The AstCSM2EVs demonstrated superior immunomodulatory capabilities by effectively polarizing macrophages toward the M2 phenotype, characterized by significant downregulation of pro-inflammatory cytokines (IL-1β, TNF-α) and concurrent upregulation of anti-inflammatory mediators (IL-4, IL-10). Notably, AstCSM2EVs exhibited enhanced angiogenic potential, evidenced by increased endothelial tube formation and elevated VEGF secretion, while simultaneously promoting osteogenic differentiation of mesenchymal stem cells through upregulated expression of key markers including ALP, BSP, and OC. Mechanistic investigations revealed that AstCSM2EVs modulated these regenerative processes primarily through miR-218-5p-mediated regulation of multiple signaling pathways, including NOD-like receptor and ECM-receptor interaction pathways. In a rabbit femoral defect model, local administration of AstCSM2EVs significantly enhanced bone regeneration, demonstrated by increased bone volume fraction and improved trabecular architecture, while effectively suppressing local inflammation. These findings establish AstCSM2EVs as a promising therapeutic agent for bone regeneration, highlighting their multifaceted roles in immunomodulation, angiogenesis, and osteogenesis. This research introduces an innovative approach that combines extracellular vesicles (EV) with immunomodulatory tissue engineering strategies to improve the treatment of bone defects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research & Development Center for x-Dimensional Extracellular Vesicles, China Medical University Hospital, Taichung, 404332, Taiwan.
- School of Medicine, China Medical University, Taichung, 406040, Taiwan.
- Department of Plastic and Reconstructive Surgery, China Medical University Hospital, Taichung, 404332, Taiwan.
- Xenotransplantation Translational Research Center, China Medical University Hospital, Taichung, 404332, Taiwan.
- Department of Biomedical Engineering, China Medical University, Taichung, 406040, Taiwan.
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, 406040, Taiwan.
Förderung
- National Science and Technology Council
- China Medical University Hospital
Zitieren
APA
Chen, C. Y., Lee, J. J., Lin, Y. H., Kuo, T. Y., Cho, D. Y., & Shie, M. Y. (2025). Osteoimmunomodulation of astragalus-calcium silicate scaffolds-activated M2 macrophage-derived miR-218-rich exosome for enhanced bone regeneration. Materials Today Bio, 35, 102286. https://doi.org/10.1016/j.mtbio.2025.102286
Vancouver
Chen CY, Lee JJ, Lin YH, Kuo TY, Cho DY, Shie MY. Osteoimmunomodulation of astragalus-calcium silicate scaffolds-activated M2 macrophage-derived miR-218-rich exosome for enhanced bone regeneration. Materials Today Bio. 2025;35:102286. doi:10.1016/j.mtbio.2025.102286
BibTeX
@article{Chen2025,
author = {Chen, Cheng-Yu and Lee, Jian-Jr and Lin, Yen-Hong and Kuo, Ting-You and Cho, Der-Yang and Shie, Ming-You},
title = {Osteoimmunomodulation of astragalus-calcium silicate scaffolds-activated M2 macrophage-derived miR-218-rich exosome for enhanced bone regeneration},
journal = {Materials Today Bio},
year = {2025},
volume = {35},
pages = {102286},
doi = {10.1016/j.mtbio.2025.102286}
}
EUVIMED